@JacobPlieth @syinvesting They are both IgG1 mAB's. Is there any reason to believe the $OMED mAB is significantly different from the $RHHBY one? $MRK seems to believe their Tigit is likely to be similar to Tiragolumab. From what i've read $BMY Tigit is differnt in how it binds to Fcγ receptors